Navigation Links
KaloBios Pharmaceuticals, Inc. Prices Public Offering of Common Stock
Date:9/26/2013

wann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or via telephone at (800) 808-7525. KaloBios intends to file a final prospectus supplement relating to the offering with the SEC, which will be available along with the accompanying prospectus filed with the SEC in connection with the shelf registration, on the SEC's website at www.sec.gov.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of KaloBios, nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is being issued pursuant to and in accordance with Rule 134 under the Securities Act of 1933, as amended.

About KaloBios Pharmaceuticals, Inc.

KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat severe medical conditions with a primary clinical focus on respiratory diseases and cancer. 

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements regarding the completion and timing of the public offering and expected use of proceeds from the public offering that involve risks and uncertainties, including, without limitation, risks related to the satisfaction of customary closing conditions. Such statements involve known and unknown risks that relate to future events or future financial performance and the actual results could differ materially from those discussed in this communication. There can be no assurance that KaloBios will be able to complete the public offering on the anticipated terms, or at all. Risks and uncertainties that may cause KaloBios's actual results to differ materially from th
'/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Herb C. Cross to Join KaloBios as Chief Financial Officer
2. KaloBios KB001 Anti-Pseudomonas Antibody Study Published in Pediatric Pulmonology
3. KaloBios to Present at Stifel Healthcare Conference 2013
4. KaloBios Reports First Quarter 2013 Financial Results
5. KaloBios to Present at Needham Healthcare Conference
6. KaloBios Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
7. KaloBios to Present at Future Leaders in the Biotech Industry Conference
8. Bioassociate Announces Initiation of Coverage on KaloBios Pharmaceuticals, Inc.
9. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
10. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
11. KaloBios Pharmaceuticals Completes Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Asterias Biotherapeutics, Inc. (NYSE ... emerging field of regenerative medicine, today announced that ... Chicago -based Rush University Medical Center ... of escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) ... complete cervical spinal cord injury (SCI). This represents ...
(Date:8/31/2015)... WOODCLIFF LAKE, N.J. and STAMFORD, ... the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and ... into a worldwide collaboration agreement for the development and ... a dual orexin receptor antagonist entering Phase III clinical ... Under the terms of the agreement, Eisai and Purdue ...
(Date:8/31/2015)... Australia , Aug. 31, 2015 Bionomics ... discovery and development of innovative therapeutics for the treatment ... cancer, today announced that its BNC101 IND submission has ... (FDA). Bionomics plans to initiate a Phase 1 clinical ... patients with metastatic pancreatic cancer prior to 31 December ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
(Date:9/1/2015)... ... September 01, 2015 , ... September is Baby Safety Month, and ... labels and stickers to keep little ones' safety top of mind at all times. ... a particular focus. According to the JPMA's Baby Safety Zone website, this year's theme ...
(Date:9/1/2015)... ... 2015 , ... Curly Hair Solutions™ is thrilled to partner ... partnership between Curly Hair Solutions™ and Trade Secrets allows for nationwide distribution of ... Curly Hair Solutions™ team could not be more delighted to see their line ...
(Date:8/31/2015)... ... 01, 2015 , ... Spinal fusion surgery – which connects ... long, arduous recovery. However, today’s minimally invasive fusions achieve similar results as traditional ... muscle damage. These advantages of minimally invasive surgery redeem the procedure’s reputation, according ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... potential patients the resources they need to have a successful cosmetic procedure; from ... plastic surgeons; Cosmetic Town Journal is always ready to help. , It is ...
(Date:8/31/2015)... ... , ... Southern Vacation Rentals – a member of the locally owned and ... property management company, 360 Blue, in support of the Sonder Project, a global ... two companies will collect any unopened food items left in vacation rentals after guest ...
Breaking Medicine News(10 mins):Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:Curly Hair Solutions™ Partners With Trade Secrets 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:Cosmetic Town: A One Stop Plastic Surgery Community 2Health News:Southern Vacation Rentals Partners with the Sonder Project 2Health News:Southern Vacation Rentals Partners with the Sonder Project 3
... (May 12, 2008) The Virginia Commonwealth University School ... $6 million from the National Institutes of Healths National ... polycystic ovary syndrome, a disorder of the endocrine system ... Polycystic ovary syndrome, or PCOS, causes hormonal imbalances leading ...
... impact and other influences are limiting the growth ... of frequency and severity of ... AOC ),the leading provider of global risk management and consulting ... care industry,finding for the first time in nine years of ...
... ... oxide material., DENVER, May 12 C5 Medical Werks, ... has submitted a 510(k),pre-market notification to the U.S. Food and ... CAD/CAM Blocks.,ZirDent(TM) is a zirconium material ideally suited to meet ...
... proposals, to expand oral health care services; awards two significant oral ... ... 12 As part of the Illinois,Children,s Healthcare Foundation,s (ILCHF) $20 million, ... is pleased to announce a request for proposals in the oral,health care ...
... games throughout the ... region, PHILADELPHIA, May ... cosponsor the Senior Games, held at,dozens of locations throughout the five-county Philadelphia region. ... each,county, beginning Monday, May 12 and continuing through the month of June.,More than ...
... trial in bladder cancer exceeds 2/3rds enrolment level ... pre-clinical work in peritoneal cancers -, BELLEVILLE, ... (TSX: BNC), a research-based, technology-driven Canadian,biopharmaceutical company, is ... non-clinical development of its proprietary platform technology:,Mycobacterial Cell ...
Cached Medicine News:Health News:NIH grant to support Translational Research Center for PCOS 2Health News:Aon Study Finds Stability in Nationwide Liability Costs in the Long Term Health Care Sector 2Health News:Aon Study Finds Stability in Nationwide Liability Costs in the Long Term Health Care Sector 3Health News:C5 Medical Werks Applies for Clearance, Certification and Licensing for the Global Marketing of ZirDent(TM) Ceramic CAD/CAM Dental Blocks 2Health News:Children in Illinois to Have Healthier Smiles 2Health News:Independence Blue Cross Supports 2008 Senior Games 2Health News:Bioniche Updates re: Mycobacterial Cell Wall Technology Platform 2Health News:Bioniche Updates re: Mycobacterial Cell Wall Technology Platform 3Health News:Bioniche Updates re: Mycobacterial Cell Wall Technology Platform 4
... KeraCel Ophthalmic Products are ... formulation of lint-free MEROCEL polyvinyl ... configured to be beneficial to ... being absorbent, and yet firm ...
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: